(function(doc, html, url) { var widget = doc.createElement("div"); widget.innerHTML = html; var script = doc.currentScript; // e = a.currentScript; if (!script) { var scripts = doc.scripts; for (var i = 0; i < scripts.length; ++i) { script = scripts[i]; if (script.src && script.src.indexOf(url) != -1) break; } } script.parentElement.replaceChild(widget, script); }(document, '

Comparing a novel inflammation biomarker and amyloid β-42 as predictors ofAlzheimer’s disease.

What is it about?

This paper examines if a novel inflammation biomarker for Alzheimer’s dementia, symmetric dimethylarginine, could differentiate normal participants from those with mild cognitive deficits. This novel biomarker was then compared to an Amyloid biomarker.

Why is it important?

It is important to develop additional biomarkers that relate to other aspects of Alzheimer's Disease in order to improve early detection of the disease.

Read more on Kudos…
The following have contributed to this page:
Elias Granadillo
' ,"url"));